title: Structural requirements of peptide YY for biological activity at enteric sites.
abstract: Peptide YY (PYY) is a colonic hormone consisting of 36 amino acids that is a potent inhibitor of pancreatic exocrine, gastric acid, and insulin secretion. The objective of the present experiments was to characterize the structural requirements of PYY for inhibition of pancreatic exocrine, gastric acid, and insulin secretion, using conscious dogs prepared with gastric and pancreatic fistulas. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (400 pmol.kg-1 x h-1) inhibited cholecystokinin-8-stimulated (25 pmol.kg-1 x h-1) pancreatic exocrine secretion (P < 0.05); however, PYY-(1-10), PYY-(1-20), PYY-(6-36), PYY-(10-36), PYY-(13-36), PYY-(24-36), and PYY-(27-36) did not inhibit pancreatic exocrine secretion. Intravenous administration of PYY-(1-36), PYY-(3-36), or PYY-(4-36) (200, 400, 800 pmol.kg-1 x h-1) inhibited pentagastrin (0.5 microgram.kg-1 x h-1)-stimulated gastric acid secretion (P < 0.05), as well as 2-deoxy-D-glucose-stimulated insulin release (75 mg/kg) in a dose-related manner. PYY-(6-36), PYY-(13-36), and [Leu31, Pro34] neuropeptide Y did not inhibit either gastric acid secretion or insulin release. In the gastric acid and insulin secretion bioassays, PYY-(1-36) was significantly more potent than PYY-(3-36) and PYY-(4-36); however, in the pancreatic exocrine secretion bioassay, the inhibitory effects of PYY-(3-36) and PYY-(1-36) did not differ significantly. PYY-(4-36) was less potent than PYY-(1-36) on pancreatic exocrine secretion.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Surgery, University of Texas Medical Branch, Galveston 77555.
authors.forename: K
authors.initials: K
authors.lastname: Yoshinaga
authors.forename: T
authors.initials: T
authors.lastname: Mochizuki
authors.forename: N
authors.initials: N
authors.lastname: Yanaihara
authors.forename: K
authors.initials: K
authors.lastname: Oshima
authors.forename: M
authors.initials: M
authors.lastname: Izukura
authors.forename: M
authors.initials: M
authors.lastname: Kogire
authors.forename: S
authors.initials: S
authors.lastname: Sumi
authors.forename: G
authors.initials: G
authors.lastname: Gomez
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: J C
authors.initials: JC
authors.lastname: Thompson
mesh_terms: D000818:Animals; D003847:Deoxyglucose / Q000494:pharmacology; D004285:Dogs; D005260:Female; D005744:Gastric Acid / Q000378:metabolism; D006207:Half-Life; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D010179:Pancreas / Q000378:metabolism; D010418:Pentagastrin / Q000494:pharmacology; D010446:Peptide Fragments / Q000494:pharmacology; D019894:Peptide YY; D010455:Peptides / Q000737:chemistry / Q000494:pharmacology / Q000502:physiology*; D012844:Sincalide / Q000494:pharmacology
chemical_list: D007328:Insulin; D010446:Peptide Fragments; D010455:Peptides; D019894:Peptide YY; C006584:1,5-anhydroglucitol; D003847:Deoxyglucose; D010418:Pentagastrin; D012844:Sincalide